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This review focuses on the development of GH receptor
antagonist as a novel agent for treatment of acromegaly,
its mechanism of action and potential areas of use. A brief
overview of acromegaly, its diagnosis and existing medi-
cal, surgical and radiotherapy options of treatment is nec-
essary to justify the addition of yet another therapeutic
modality to the already vast therapeutic armamentarium.
Introduction
Acromegaly is a multisystem disease due to chronic hy-
persecretion of growth hormone (GH) from a pituitary
adenoma [1]. The resultant increase in insulin like growth
factor (IGF-1) causes somatic overgrowth whereas ele-
vated GH on its own promotes certain metabolic derange-
ments such as glucose intolerance or diabetes. Extension
of the pituitary tumor outside the confines of the sella may
cause ophthalmoplegia and chiasmal compression. The
mortality and morbidity of acromegaly are determined by
GH/IGF-1 induced end organ damage such as cardiomy-
opathy, arrthymias, sleep apnea, diabetes and osteoarthri-
tis in addition to mass effects of tumor and accompanying
hypopituitarism [2–5].
Diagnosis
The diagnosis of acromegaly essentially rests on a combi-
nation of physical findings, elevated GH and IGF-1 levels
and inability of an oral glucose load to suppress plasma
GH [6,7]. The biochemical criteria for the diagnosis and
surveillance of acromegaly have changed over the years as
a result of several epidemiological studies analyzing the
mortality of acromegaly as a function of prevailing GH
milieu [7,8].
Whereas many treated and even newly diagnosed pa-
tients may have random or mean daily GH levels within the
“normal” range, the trough or interpulse GH concentra-
tions are uniformly elevated in patients with active disease
[9]. This feature of GH hypersecretion will be obviously
missed unless a frequent (Q10–20 min) and prolonged
(12–24 hr) blood sampling is performed. On the other
hand, a single value of plasma IGF-1 faithfully reflects
both the total daily GH output as well as the prevailing
pattern of GH secretion [8,9]. Plasma IGF-1 needs to be
interpreted according to strict age/ gender adjusted norma-
tive values. The criteria for glucose suppressed GH have
also changed markedly. According to strict contemporary
criteria, plasma GH needs to fall below 0.2–0.25ug/l to
be defined as a manifestation of a normal physiological
response [10–12]. Failure of GH to suppress normally
(even in the presence of normal IGF-1) may potentially
predict higher probability of recurrence. Thus, both GH
(glucose suppressed) and IGF-1 are valuable parameters
to be assessed in patients with acromegaly. Plasma GH
is a more sensitive indicator of acute changes in tumor
activity (i.e, after surgery, radiotherapy, dopamine and so-
matostatin analogues) whereas IGF-1 is an infinitely bet-
ter parameter of overall normalcy of GH secretion and
the clinical activity of acromegaly (arthropathy, soft tissue
volume, perspiration, sleep apnea etc). Both GH (<1–2.5
ug/l) and IGF-1 (age/gender normal) have been shown to
predict normalization of subsequent mortality rates [4,5].
The size and the invasiveness of the pituitary adenoma is
best assessed by MRI.
Thus, the goals of therapy can be subdivided into 3
categories:
(1) Primary: normalization of plasma IGF-1 and abolition
of the mass effects of the tumor.
(2) Secondary: therapy of associated morbidities
(arthropathy, diabetes, arrhythmias etc.) and re-
placement of missing pituitary hormones in case of
hypopituitarism.
(3) Ultimate: normalization of mortality rates and pre-
vention of recurrence.
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Practical Aspects of Treatment of Acromegaly
Therapeutic choices for management of acromegaly are
largely dictated by age and general health of the patient
as well as efficacy, complications and risks of a particu-
lar therapeutic modality. General consensus [12] is that
trans-sphenoidal adenomectomy is the first line therapy
followed by medical therapy if the former is not curative.
In some patients with unacceptable cardiovascular, sur-
gical or anesthetic risks and adenomas not impinging on
the optic chiasm, or those whose tumor is surgically in-
accessible (e.g., largely confined to the cavernous sinus),
primary medical therapy may be offered. If a maximum
dose of medications fails to achieve remission and the
tumor continues to grow, radiotherapy needs to be consid-
ered. Reoperation or treatment with GH receptor antago-
nist should be considered for patients resistant to surgical
or medical approaches.
Surgery
Surgery is the cornerstone of therapy and procedure of
choice for initial management. The success of surgery de-
pends on the experience of the surgeon on the one hand
and on the characteristics of the tumor (size, invasiveness,
consistency) on the other hand. The former is exempli-
fied by the wide variability of proportion of patients with
post-operative GH <2.5 ug/l in different treatment centers
[13,14]. The overall success rate even in the best neurosur-
gical centers is about 50% [13,14]. Some 85% of patients
with microadenomas achieve normal IGF-1 levels post
surgery, but the success rate plummets in patients with
macroadenomas. Invasiveness of the tumor into the sur-
rounding tissues (cavernous sinus especially) precludes
curative outcome.
Complications of Surgery
Surgical damage of pituitary can lead to permanent hy-
popitutarism and result in need for lifelong hormone re-
placement. CSF rhinorrhea, visual impairment, sinusitis
and hemorrhage are seen in a small number of patients.
The likelihood of complications is directly related to the
experience of the neurosurgeon, the size of the tumor
and is more common after subfrontal rather than trans-
sphenoidal surgery.
Radiotherapy
Radiation has been used as a therapeutic modality for
acromegaly since 1909. Current modalities include con-
ventional external radiotherapy (XRT) and stereotactic
approaches (proton beam,gamma knife and LINAC). XRT
is usually administered over four to six weeks in daily
fractions to a total dose of 45–50 Gy. In most patients GH
levels fall by about 50% in the first 1–2 years and continue
to decrease slowly thereafter [15,16]. Medical therapy is
often required to bridge the latency period until radiother-
apy becomes effective. Multiple studies have reported
declines in GH levels for up to 20–25 years, with ultimate
GH values below 5 ug/l in 70–90% of cases [16]. Review
of published data [17,18] however have shown that radia-
tion therapy is much less effective than previously thought
when its efficacy is judged by modern criteria. Radiation
therapy was found to normalize IGF-1 levels in only 1/3
of patients after 10 years [18,19]. Understandably the
patients with the highest initial GH levels fare the worst.
Hypopituitarism develops in 50–70% of patients and in
rare cases XRT may cause optic nerve damage and oph-
thalmoplegia. Radiation vasculopathy increases the risk of
cerebrovascular accidents by 2–4 fold [20] and there is a
1–2% risk of developing radiation induced malignant
tumors [21] incidence of neurocognitive deficits with
significant memory loss and depression had never been
quantified but many post radiation patients have these
complaints.
Stereotactic radiosurgery (SRS)
Stereotactic radiosurgery modalities include use of a lin-
ear accelerator, gamma knife and proton beam [22]. Their
advantage over XRT is largely limited to the need for only
a single dose procedure. Rigid target fixation and comput-
erized image acquisition optimize targeting and minimize
radiation field scatter.
Although only limited data are available and the dura-
tion of follow-up was relatively short, summary of avail-
able data [19,23] does not demonstrate any superiority of
stereotactic radiosurgery over conventional radiotherapy
as judged by final IGF-1 values. It is also still uncertain
whether SRS has a more rapid effect. Since only small
tumor remnants are suitable for SRS, the low initial GH
levels in this population of patients introduce a bias in fa-
vor of a seemingly more rapid normalization of plasma
GH. The rate of side effects is comparable between the
two modalities, but the risk of local neurotoxicity (chias-
mal or temporal lobe damage) may be higher with SRS if
the planning was faulty.
Dopamine Receptor Agonists
Dopamine stimulates GH release in normal individuals but
paradoxically inhibits it in subjects with GH secreting ade-
noma. Review of meta- analysis of published studies [24]
showed that daily doses of bromocriptine at 5–80 mg/day
in 549 patients normalized IGF-1 in less than 10% of
patients. Newer agents like quinagolide and cabergoline
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have longer duration of action, higher specificity for the
dopamine receptor and greater efficacy and have been
shown to be better tolerated [25]. The largest study of
patients with Cabergoline showed normalization of IGF-
1 levels in 39% of patients [25] but other groups failed
to confirm these results. Overall, dopamine agonists are
only rarely effective, but their oral route of administration
makes them attractive enough to attempt their use on at
least a trial basis.
Somatostatin Analogues
Five somatostatin receptor subtypes, SSTR1-5, each en-
coded on a separate chromosome are responsible for a
variety of heterogenous effects of somatostatin (SRIF) in
different organs and tissues. SSTR2 and 5 are predomi-
nant subtypes expressed in the normal pituitary and inhibit
GH and TSH release. In vitro, somatostatin retains its in-
hibitory effect on GH secreting tumors and this has led to
the development of somatostatin analogs for clinical use
in the treatment of acromegaly [26]. Octreotide is an oc-
tapeptide that is almost selectively SSTR2 specific. It has
in vivo half life of 2 h, and inhibits GH secretion with 45
fold greater potency than native SRIF [27]. A single sc
injection suppresses GH secretion for up to 8 h.
Octreotide LAR is a formulation prepared as slowly
bio-degrading polymer which allows prolonged release
of the drug. Steady state conditions are achieved after
2–3 monthly I.M injections at which time the maximal
suppression of GH and IGF-1 can be observed. Although
recommended by the manufacturer to be given as monthly
doses, the long half life often enables once every 6–8 week
dosing.
Lanreotide is available in Europe and is another long
acting somatostatin analog administered as intramuscular
injections once every 7–14 days. Lanreotide autogel, a
new galenic form is a pure aqueous solution of lanreotide
and can be administered by deep sc injections every 28
days [28].
All SRIF analogs inhibit GH secretion and IGF-1 levels
in patients with acromegaly. Their efficacy is dose depen-
dant and inversely proportional to baseline GH concentra-
tions [28,29] Overall they normalize IGF-1 concentrations
in up to 60% of patients. Additionally they are capable of
shrinking pituitary somatotropinomas in the majority of
cases, although the degree of shrinkage is highly variable,
between 20–80% [30]. Most importantly, they effectively
prevent future tumor growth. Some patients however are
either insensitive to the drug or have unacceptable degree
of side effects.
A new analog, SOM 230 binds to all the SSTR’s ex-
cept subtype 4 and has 40 higher fold affinity for SSRT5
than octreotide. SOM 230 is more potent in inhibiting GH
secretion compared to octreotide in cultured rat pituitary
cells and in vivo in animals [31]. This novel peptide is
currently in Phase 2 trials.
The main side effects of all somatostatin analogs are
diarrhea, nausea, abdominal pain and pain at the injection
site. Gallstones which are usually asymptomatic are seen
in 3–12% of patients [29]. Their formation is thought to
be due to inhibition of gall bladder emptying and CCK
secretion. Long acting somatostatin analogs were equally
effective as primary or secondary therapy. Symptoms such
as soft tissue swelling, increased perspiration, fatigue
and arthritis improved in 50–100% of patients when the
drug was used as primary therapy in acromegaly [28,29].
Headache appears to improve better with short acting than
long acting analogs. Manifestation of cardiovascular dis-
ease, primarily LVH and ejection fraction improve with
normalization of IGF-1. There is also reduction of joint
thickening and sleep apnea.
In summary, surgery and radiation are potentially cu-
rative modalities and carry a one time price tag. However
they are either very operator dependant (surgery) or slow
acting and neurotoxic (radiation). Dopamine agonists are
very ineffective and may be used in occasional patients
only. SRLs accomplish both biochemical and tumor re-
straining goals of therapy but are not always effective and
quite expensive in the long run.
Importantly, all of the above modalities work at the
level of the tumor and their efficacy is determined by the
peculiarities of the neoplastic tissue: rate of growth, fibro-
sis, radioresistance, presence of dopamine or somatostatin
receptors.
Alternative approaches to treatment of acromegaly
would be aimed at preventing GH action rather than sup-
pressing its secretion. Two experimental models—fasting
[32,33] and estrogen therapy [34,35] provided initial clues
to that approach.
Early studies have shown that high doses of estrogen
seem to offer clinical benefits to patients with acromegaly
[34,35]. Subsequently it was shown that estrogen antago-
nizes GH signal transduction by suppressing JAK-2 phos-
phorylation [36]. Raloxifene, a SERM, suppressed plasma
IGF-1 in acromegalic women [37] and men [38], but IGF-1
normalization was only seldom seen.
Fasting was shown to decrease the abundance of GHR
mRNA in the liver and other tissues in rats and Ho et al.
have shown that fasting lowers circulating IGF-1 in pa-
tients with acromegaly at the same rate as in normal con-
trols [33]. Both after fasting and after estrogen plasma GH
increases as a result of disruption of the negative feedback
loop.Thus fasting and estrogen can lower plasma IGF-1 in
patients with acromegaly by lowering GHR number or by
interfering with the GH signal transduction. Unfortunately
neither of these modalities can be used practically.
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Pegvisomant
The scientific discovery of GH receptor antagonist Pegvi-
somant began 15 years ago with the elucidation of the
structure- function relationship of GH and its receptor.
GH is a 22 Kda polypeptide with 191 amino acids, 2 disul-
phide bonds and four alpha helices. It is synthesized in the
somatotrophic cells of the anterior pituitary and is cen-
tral to the regulation of growth and differentiation primar-
ily modulating gene expression and metabolism in target
tissues. It has numerous other biological effects includ-
ing enhancement of milk production, nitrogen retention,
lipolysis and diabetogenic effects. Although GH may have
direct metabolic effects on peripheral tissues most of its
growth promoting effects are mediated by IGF-1 (insulin
like growth factor), a member of the insulin like peptide
family. GH binding to the extracellular portion of the re-
ceptor is followed by the dimerization of GHR and initia-
tion of the GH signaling [39,40]. The GH molecule has 2
separate receptor binding domains: site 1 and site 2. The
secondary structure of GH consists of four α helix core
with 2 disulphide bonds, such that noncontiguous regions
of the aminoacid chain contribute to the two binding re-
gions. Site 1 is made up of the loop between aminoacid
residues 54 and 74 at the C terminal half of helix four and
N terminal region of helix one. The N terminal residues of
the first and third helices contribute to binding site 2. Once
GH binds to the initial GH receptor via site 1, a second
identical receptor is recruited by site 2, leading to receptor
dimerization and subsequent cellular activation (Fig. 1).
Glycine in the third α helix of GH is particularly important
for GH’s biological activity. If it is replaced with variety of
other amino acids, GH is converted from growth enhancer
to a growth suppressor or GH antagonist (Fig. 2). Kopchick
et al. [39–41] demonstrated that the GH antagonist could
inhibit the cell differentiation promoting activities of GH
on mouse pre-adipocytes at equimolar concentrations. The
lipolytic and insulin like activities of GH were completely
inhibited by 10 fold excess of GH antagonist using rat
adipose tissues. Transgenic mice that express a GH mu-
tant with the so called perfect amphiphilic helix 3 have
decreased circulating insulin like growth factor (IGF-1)
concentrations and exhibit a dwarf phenotype. By com-
bining site specific mutagenesis of the GH gene with an in
vivo assay of the ability of GH analogs to regulate growth
of transgenic mice, a GH antagonist was discovered. Thus,
GH antagonists acted to inhibit GH action both in vivo and
in vitro.
Creation of pegvisomant
Pegvisomant is a GH analog that includes single amino
acid substitution at position 120 within binding site 2
which prevents its binding to GH receptor [41] (Fig. 2).
Fig. 1. Schematic representation of GH-GHR interaction and
biological effects.
The additional changes included 8 amino acid substitu-
tions within binding site 1 that actually increase its bind-
ing properties and PEG moieties that increase half life
and reduce immunogenecity of the molecule. When the
resulting GHR antagonist molecule- the original substitu-
tion of Gly 120 at site 2 as well as eight mutations in site
1- was combined with PEG 5000, the final molecule was
shown to maintain GHR binding and antagonistic prop-
erties with extended half life of 100 hours. The generic
name is pegvisomant and trade name is Somavert.
Pegvisomant Efficacy
The relatively long half life of Pegvisomant allows once
daily subcutaneous administration. Pegvisomant, if given
in sufficient quantities, has been shown to normalize IGF-
1 levels in almost all patients with acromegaly in a dose
dependant fashion. In a randomized trial [43] of 112 pa-
tients for 12 weeks with increasing doses of pegvisomant
10, 15 and 20 mg per day, it was found that serum IGF-
1 levels normalized in 90% of patients with acromegaly
with significant improvement in signs and symptoms such
as soft tissue swelling, excessive perspiration and fatigue
[43–45]. In longer term studies, pegvisomant decreased
IGF-1 levels in 97% of 90 patients treated for more than
12 months using up to 40 mg/day [47]. Also corrected were
the metabolic defects of acromegaly such as insulin resis-
tance and changes in cortisol and lipid metabolism [48,49]
GH induces gluconeogenesis and lipolysis, resulting in
increased blood glucose and FFA and this is reversible
in patients with acromegaly during pegvisomant therapy
[43,47]. A single injection of pegvisomant rapidly sup-
pressed IGF-1 levels by 31% and enhanced GH secretion.
An increase in plasma GH within days of initiating chronic
Pegvisomant therapy was also observed [47]; within 2
weeks, plasma GH concentrations plateaued at 2–3 times
basal levels. The decrease in IGF-1 levels correlated with
the increase in GH burst amplitude [50].
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Fig. 2. Schematic representation of GH- GH-A- GHR interaction and inhibition of biological effects.
Long term clinical efficacy
A second study [47] was done after the initial 12 week
trial and pegvisomant injections were given to 160 pa-
tients for 6 months (n = 131), 12 months (n = 90) and
for 18 months (n = 39) to evaluate the long term effi-
cacy. Development of GH antibodies was evaluated peri-
odically and MRI of the pituitary was done every 6 months
to evaluate potential changes in tumor size. No change in
mean tumor size was observed, however GH levels in-
creased in the first 2 weeks of therapy. There was no ad-
ditional increase in GH levels thereafter and no evidence
of tachyphylaxis. Of note, the serum IGF-1 levels normal-
ized in 97% of patients with a dose of up to 80 mg/day for
12 months.
Long term therapy with pegvisomant caused improve-
ment in metabolic parameters of acromegaly such as re-
duction of fasting insulin levels and corresponding fall in
serum glucose concentrations [51,52]. Van der Lely et al.
[47] reported a significant decrease in fasting serum in-
sulin and glucose levels in patients treated with pegviso-
mant for 18 months. Rose and Clemmons [52] observed
that in 4 out of five patients normalization of IGF lev-
els was accompanied by improvement in insulin sensi-
tivity. This was associated with a fall in fasting insulin
levels enabling one of the patients to discontinue oral hy-
poglycemic agent, another one to switch from insulin to
oral anti- diabetic agent and the third one to decrease in-
sulin dose by 50%. In another study, conversion of pa-
tients from LAR to pegvisomant resulted in significant fall
in HbA1C and glucose levels [51]. Thus GH antagonist
therapy lowered insulin levels and glucose and improved
insulin sensitivity.
There was development of anti pegvisomant antibodies
in 17% of patients, but titres were low and not accompa-
nied by tachyphylaxis. Elevation of hepatic enzymes had
been observed in less than 1% of patients and returned to
normal with the cessation of pegvisomant. Also the tumor
size increased only in 2 of the patients requiring further
therapy with irradiation but these tumors appeared to be
invasive at the outset.
Since then additional 8 patients out of a total cohort of
about 600 patients were shown to increase the tumor size
during pegvisomant therapy. It is still unknown whether
the decline in IGF-1 was the causative factor (analogous to
the development of Nelson’s syndrome) or just a propen-
sity of some tumors to grow irrespective of any external
influence.
Thus, overall, pegvisomant is remarkably effective in
normalizing plasma IGF-1 and abrogating the metabolic
effects of elevated GH. The more widespread use of this
drug is limited by its cost, the relative inconvenience of
daily injections (as opposed to monthly administration
of somatostatin analogues), lack of efficacy against the
headache and the uncertainity about its effects on tumor
progression.
Safety and Tolerability
In summary, Pegvisomant lowered IGF-1 levels and im-
proved insulin sensitivity in patients with acromegaly.
There is no evidence of tachyphylaxis [47] although there
is some development of antibodies. The general guidelines
for follow-up include monitoring tumor size with MRIs
semiannually and then yearly for the first few years un-
less the tumor is known to be actively growing in which
case earlier exams may be required. Also visual perimetry
is recommended for patients with visual problems before
surgery and in patients with macroadenomas and residual
extrasellar tumors after surgery.
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The main side effects of Pegvisomant therapy are in-
jection site reactions (10%), deranged liver function tests
(elevated AST and ALT) and increase in pituitary tumor
size [46,47]. The latter two side effects occur in less than
1% of patients.
Future Directions
Indirect and early experimental data suggest that GH re-
ceptor antagonists can be potentially used not only in the
treatment of acromegaly but also in cancer and diabetes.
Diabetic retinopathy
Modulation of IGF-1/GH axis in diabetic patients have
implications in microvascular complications of diabetes
as was first noted in patients with pituitary ablation that
arrested the progression of diabetic retinopathy. GH has
been shown to stimulate proliferation of human retinal
microvascular endothelial cells in vitro. There has been a
positive correlation between GH concentration and pro-
gression of diabetic retinopathy [53]. Over expression of
IGF-1 in retinal tissue promotes retinopathy and GH re-
ceptor antagonists protect from ischemia induced retinal
neovascularization. The role of GH in diabetic retinopathy
was studied by Smith et al. using dwarf transgenic mice
expressing GH receptor antagonist gene and normal mice
given inhibitor of GH secretion, MK 678 [53]. In both
groups retinal neovascularization was inhibited. This was
inversely proportional to the decline in serum IGF-1 levels
and was reversed by addition of exogenous IGF-1. This
suggests that systemic inhibition of GH or IGF-1 or both
may have a therapeutic role in preventing retinopathy.
However direct human study in patients with estab-
lished diabetic retinopathy failed to substantiate the ben-
eficial effects of pegvisomant on disease progression.
Beck et al. [54] studied effects of GH receptor antago-
nist in 25 patients with diabetes mellitus and proliferative
retinopathy and found no evidence of regression of di-
abetic retinopathy. The extent of neovascularization was
unchanged in 16 patients and there was some progres-
sion in 9 patients treated with daily injections of 20 mg of
Pegvisomant. The authors concluded that the lack of effect
could be due to the improvement in overall diabetes con-
trol seen in their patients as part of pegvisomant induced
improvement of insulin sensitivity and the known asso-
ciation of worsening of retinopathy initially with better
glycemic control.
Diabetic nephropathy
In both humans and animals, GH and insulin like growth
factors (IGF-I & II) have been implicated in the de-
velopment of diabetic microangiopathy which includes
nephropathy and glomerulosclerosis [55]. The role of IGF
system in the development of kidney disease was shown
in insulinopenic diabetes model produced by Streptozo-
tocin in rats [56]. In early experimental diabetes a transient
increase in kidney IGF-1 mRNA is a consistent finding
followed by renal and glomerular growth. Chen et al. [56]
showed that transgenic mice expressing GH antagonist
were protected from diabetes induced glomerulosclerosis
and GH induced nephropathy. This suggested a causative
relationship between elevated IGF-1 and morphological
and hemodynamic changes seen with nephropathy. Stud-
ies by Landau et al. confirm that GH/IGF-1 axis plays an
important role in early diabetic renal changes and spe-
cific GH antagonists could be a novel therapy to pre-
vent diabetic nephropathy. They [55,56] showed that STZ
induced diabetic rats had prominent changes in IGF-1
and IGFBP gene expression with pronounced increase in
IGFBP-1 mRNA in renal cortex. This increased IGFBP-1
mRNA expression causes IGFBP’s to act as carriers of
IGF-1 which may operate as local modulators of IGF ac-
tion in various physiological and pathological conditions.
The authors demonstrated an early accumulation of IGF-
1 in kidneys before the onset of renal enlargement and
elevated GFR and renal plasma flow and suggested that
there was a causal relationship between elevated IGF-1
and the morphological and hemodynamic changes. The
rats then had sustained elevated levels of IGF-1 for 6
months after induction of diabetes during the development
of thickening of basal membrane and elevation of urinary
albumin excretion. This suggested that IGF-1 played a
strong role in the patho-physiological process associated
with long term diabetic renal disease It is not yet known
whether Pegvisomant may have a preventative effect in
development of renal lesions and end organ damage in
diabetic patients or may even reverse the already existing
damage.
Interestingly, Pegvisomant had no effect on renal ex-
pression of GH/IGF-1 axis proteins like IGFBP-3 and
GHR in STZ induced diabetic rats. These rats when in-
jected with daily G-120 PEG every day for 3 weeks com-
pared to their age matched hyperglycemic counterparts,
were found to have reduction in glomerular hypertrophy,
GHR mRNA levels in kidney and normalization of uri-
nary albumin excretion. Thus the GH receptor antagonist
appears to have protective effects over the kidney in dia-
betes, preventing the development of nephropathy [56,57].
Human studies will be needed to test this hypothesis
clinically.
Cancer
Two potential targets for pegvisomant therapy can be con-
templated: prevention of cancer development and modifi-
cation of growth of the already existing tumors. The role
of IGF-1 in inducing prostate, breast and colon cancers
GH Receptor Antagonist: Mechanism of Action and Clinical Utility 11
has been suggested from some epidemiological studies
[58,59]. IGF-1 is shown in experimental studies to induce
the proliferation and anti-apoptotic effects of colon can-
cer cell lines [59]. Colon cancers constitute 18% of all
cancers in acromegaly and the mechanism is thought to
be the increased epithelial cell proliferation rate induced
by IGF-1/ GH excess [60]. This then reduces apoptotic
rate and may induce the accumulation of genetic defects
leading to cancer of the colon [61,62]. In vivo progression
and metastatic potential of human colon cancer explants
were significantly inhibited in LID mice (liver specific
IGF-1deficient) and both markedly increased by adminis-
tration of recombinant IGF-1 [64].
IGF-1 is found to have a mitogenic and anti-apoptotic
effect and is thought to have a role in inducing breast can-
cer particularly in premenopausal women [64]. GH recep-
tor antagonists may be useful in this case as they can sig-
nificantly reduce IGF-1 levels. Raloxifene has been shown
to reduce IGF-1 levels and attenuate the development of
breast cancer in women [65]. Pollack et al. [66] have also
shown that GH antagonist transgenic mice have resistance
to progression of breast tumors induced by 9, 10 Dimethyl-
1,2-benzanthracene (DMBA). After a 39 week treatment
with DMBA, 68% of GH antagonist treated mice were
without tumors as opposed to 31% of control mice. The
protective effect of GH receptor antagonist was reversed
with the administration of recombinant IGF-1.
IGF-1 is a mitogen which can increase the H3 thymi-
dine incorporation in primary cultures of human menin-
gioma cells and Pegvisomant not only inhibited the incor-
poration but also the growth of the human meningioma
cells [67].
This clearly suggests that GH receptor antagonists may
have a beneficial role in GH/IGF-1 dependant cancers and
may reduce risk of developing these cancers.
Summary
Pegvisomant, a GHR antagonist that was introduced into
the armamentarium of therapy for acromegaly is a signif-
icant therapeutic advance based on its unique mechanism
of action as a peripheral GH antagonist. Unlike somato-
statin analogs and dopamine agonists which bind to spe-
cific pituitary tumor receptors and act by inhibiting GH
secretion, Pegvisomant acts by blocking GH action at the
site of GH receptor peripherally. As a consequence, GH
levels may rise and cannot be used as a marker of disease
activity but IGF-1 levels are the primary measure of effi-
cacy of therapy. The long term studies with doses up to
40 mg/day for up to 18 months have shown normaliza-
tion of IGF-1 in 97% of patients with acromegaly without
development of tachyphylaxis. However the still linger-
ing uncertainty about the potential increase in pituitary
tumor size clearly requires some resolution in subsequent
studies.
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